Vertex Pharma projects steady 2026 revenue, anticipates growth in cystic fibrosis drugs

• The company expects at least $500 million in 2026 revenue from non-cystic fibrosis products, including Casgevy (which treated 64 patients in 2025 and generated $54 million in Q4) and Journavx (which received over 550,000 prescriptions through year-end 2025)
• Vertex secured commercial coverage for Journavx with all three national pharmacy benefit managers, expected to boost uptake in 2026 following its 2025 approval for acute pain
• The company plans to release interim data in H1 2026 for experimental drug povetacicept for kidney disease, using a priority review voucher to expedite FDA review from ten months to six

Vertex Pharmaceuticals Projects Steady 2026 Revenue Growth

Vertex Pharmaceuticals forecasted 2026 revenue between $12.95 billion and $13.1 billion, with the midpoint aligned with analyst estimates of $13.02 billion. The Boston-based drugmaker anticipates growth from its dominant cystic fibrosis (CF) franchise while expanding into new therapeutic areas.

Diversification Strategy

The company expects at least $500 million in 2026 revenue from non-CF products, including:

• Casgevy: Gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia, generating $54 million in Q4 2025 with 64 patient infusions during the year
• Journavx: Non-opioid painkiller approved in 2024, receiving over 550,000 prescriptions through year-end 2025. The drug now has commercial coverage from all three national pharmacy benefit managers, expected to drive uptake in 2026.

Q4 2025 Performance

Fourth-quarter revenue rose 10% to $3.19 billion, meeting analyst expectations of $3.18 billion. Growth was driven by strong CF therapy performance and contributions from newer products. Adjusted earnings reached $5.03 per share.

Pipeline Development

Vertex remains on track to release interim data for povetacicept, an experimental kidney disease treatment, in the first half of 2026. The company is utilizing a priority review voucher to accelerate FDA review from ten months to six.

Market Implications

Vertex's diversification beyond CF demonstrates strategic expansion into high-value markets including gene therapies and pain management. The strong prescription uptake for Journavx and increasing Casgevy infusions signal successful commercialization of newer products, positioning the company for sustained growth beyond its core CF franchise.